1
|
Tiklová K, Gillberg L, Volakakis N, Lundén-Miguel H, Dahl L, Serrano GE, Adler CH, Beach TG, Perlmann T. Disease Duration Influences Gene Expression in Neuromelanin-Positive Cells From Parkinson's Disease Patients. Front Mol Neurosci 2021; 14:763777. [PMID: 34867188 PMCID: PMC8632647 DOI: 10.3389/fnmol.2021.763777] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 10/19/2021] [Indexed: 11/13/2022] Open
Abstract
Analyses of gene expression in cells affected by neurodegenerative disease can provide important insights into disease mechanisms and relevant stress response pathways. Major symptoms in Parkinson’s disease (PD) are caused by the degeneration of midbrain dopamine (mDA) neurons within the substantia nigra. Here we isolated neuromelanin-positive dopamine neurons by laser capture microdissection from post-mortem human substantia nigra samples recovered at both early and advanced stages of PD. Neuromelanin-positive cells were also isolated from individuals with incidental Lewy body disease (ILBD) and from aged-matched controls. Isolated mDA neurons were subjected to genome-wide gene expression analysis by mRNA sequencing. The analysis identified hundreds of dysregulated genes in PD. Results showed that mostly non-overlapping genes were differentially expressed in ILBD, subjects who were early after diagnosis (less than five years) and those autopsied at more advanced stages of disease (over five years since diagnosis). The identity of differentially expressed genes suggested that more resilient, stably surviving DA neurons were enriched in samples from advanced stages of disease, either as a consequence of positive selection of a less vulnerable long-term surviving mDA neuron subtype or due to up-regulation of neuroprotective gene products.
Collapse
Affiliation(s)
- Katarína Tiklová
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.,Ludwig Institute for Cancer Research, Stockholm, Sweden
| | - Linda Gillberg
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.,Ludwig Institute for Cancer Research, Stockholm, Sweden
| | | | | | - Lina Dahl
- Ludwig Institute for Cancer Research, Stockholm, Sweden
| | - Geidy E Serrano
- Banner Sun Health Research Institute, Sun City, AZ, United States
| | - Charles H Adler
- Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, United States
| | - Thomas G Beach
- Banner Sun Health Research Institute, Sun City, AZ, United States
| | - Thomas Perlmann
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
2
|
Silva-Adaya D, Garza-Lombó C, Gonsebatt ME. Xenobiotic transport and metabolism in the human brain. Neurotoxicology 2021; 86:125-138. [PMID: 34371026 DOI: 10.1016/j.neuro.2021.08.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 08/02/2021] [Accepted: 08/04/2021] [Indexed: 02/06/2023]
Abstract
Organisms have metabolic pathways responsible for eliminating endogenous and exogenous toxicants. Generally, we associate the liver par excellence as the organ in charge of detoxifying the body; however, this process occurs in all tissues, including the brain. Due to the presence of the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB), the Central Nervous System (CNS) is considered a partially isolated organ, but similar to other organs, the CNS possess xenobiotic transporters and metabolic pathways associated with the elimination of xenobiotic agents. In this review, we describe the different systems related to the detoxification of xenobiotics in the CNS, providing examples in which their association with neurodegenerative processes is suspected. The CNS detoxifying systems include carrier-mediated, active efflux and receptor-mediated transport, and detoxifying systems that include phase I and phase II enzymes, as well as those enzymes in charge of neutralizing compounds such as electrophilic agents, reactive oxygen species (ROS), and free radicals, which are products of the bioactivation of xenobiotics. Moreover, we discuss the differential expression of these systems in different regions of the CNS, showing the different detoxifying needs and the composition of each region in terms of the cell type, neurotransmitter content, and the accumulation of xenobiotics and/or reactive compounds.
Collapse
Affiliation(s)
- Daniela Silva-Adaya
- Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico; Laboratorio Experimental de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Mexico, 14269, Mexico
| | - Carla Garza-Lombó
- Department of Pharmacology and Toxicology, The Stark Neurosciences Research Institute, Indiana University School of Medicine, 320 West 15th Street, NB, Indianapolis, IN, 46202, USA
| | - María E Gonsebatt
- Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico.
| |
Collapse
|
3
|
Bjørklund G, Peana M, Maes M, Dadar M, Severin B. The glutathione system in Parkinson's disease and its progression. Neurosci Biobehav Rev 2020; 120:470-478. [PMID: 33068556 DOI: 10.1016/j.neubiorev.2020.10.004] [Citation(s) in RCA: 73] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 09/25/2020] [Accepted: 10/05/2020] [Indexed: 02/07/2023]
Abstract
Redox dysfunctions and neuro-oxidative stress play a major role in the pathophysiology and progression of Parkinson's disease (PD). Glutathione (GSH) and the reduced/oxidized glutathione (GSH/GSSG) ratio are lowered in oxidative stress conditions and may lead to increased oxidative toxicity. GSH is involved not only in neuro-immune and neuro-oxidative processes, including thiol redox signaling, but also in cell proliferation and differentiation and in the regulation of cell death, including apoptotic pathways. Lowered GSH metabolism and a low GSH/GSSG ratio following oxidative stress are associated with mitochondrial dysfunctions and constitute a critical factor in the neuroinflammatory and neurodegenerative processes accompanying PD. This review provides indirect evidence that GSH redox signaling is associated with the pathophysiology of PD. Nevertheless, it has not been delineated whether GSH redox imbalances are a causative factor in PD or whether PD-associated pathways cause the GSH redox imbalances in PD. The results show that antioxidant approaches, including neuroprotective and anti-neuroinflammatory agents, which neutralize reactive oxygen species, may have therapeutic efficacy in the treatment of PD and its progression.
Collapse
Affiliation(s)
- Geir Bjørklund
- Council for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway.
| | | | - Michael Maes
- Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Impact Research Center, Deakin University, Geelong, Australia
| | - Maryam Dadar
- Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
| | - Beatrice Severin
- Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania
| |
Collapse
|
4
|
Ellwanger JH, Franke SIR, Bordin DL, Prá D, Henriques JAP. Biological functions of selenium and its potential influence on Parkinson's disease. AN ACAD BRAS CIENC 2016; 88:1655-1674. [PMID: 27556332 DOI: 10.1590/0001-3765201620150595] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Accepted: 09/28/2015] [Indexed: 03/01/2023] Open
Abstract
Parkinson's disease is characterized by the death of dopaminergic neurons, mainly in the substantia nigra, and causes serious locomotor dysfunctions. It is likely that the oxidative damage to cellular biomolecules is among the leading causes of neurodegeneration that occurs in the disease. Selenium is an essential mineral for proper functioning of the brain, and mainly due to its antioxidant activity, it is possible to exert a special role in the prevention and in the nutritional management of Parkinson's disease. Currently, few researchers have investigated the effects of selenium on Parkinson´s disease. However, it is known that very high or very low body levels of selenium can (possibly) contribute to the pathogenesis of Parkinson's disease, because this imbalance results in increased levels of oxidative stress. Therefore, the aim of this work is to review and discuss studies that have addressed these topics and to finally associate the information obtained from them so that these data and associations serve as input to new research.
Collapse
Affiliation(s)
- Joel H Ellwanger
- Programa de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul/UFRGS, Campus do Vale, Prédio 43421, Av. Bento Gonçalves, 9500, 91501-970 Porto Alegre, RS, Brasil
| | - Silvia I R Franke
- Programa de Pós-Graduação em Promoção da Saúde, Universidade de Santa Cruz do Sul/UNISC, Bloco 42, sala 4206, Av. Independência, 2293, Universitário, 96815-900 Santa Cruz do Sul, RS, Brasil
| | - Diana L Bordin
- Programa de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul/UFRGS, Campus do Vale, Prédio 43421, Av. Bento Gonçalves, 9500, 91501-970 Porto Alegre, RS, Brasil
| | - Daniel Prá
- Programa de Pós-Graduação em Promoção da Saúde, Universidade de Santa Cruz do Sul/UNISC, Bloco 42, sala 4206, Av. Independência, 2293, Universitário, 96815-900 Santa Cruz do Sul, RS, Brasil.,Departamento de Biologia e Farmácia, Universidade de Santa Cruz do Sul/UNISC, Bloco 12, sala 1206, Av. Independência, 2293, Universitário, 96815-900 Santa Cruz do Sul, RS, Brasil
| | - João A P Henriques
- Programa de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul/UFRGS, Campus do Vale, Prédio 43421, Av. Bento Gonçalves, 9500, 91501-970 Porto Alegre, RS, Brasil.,Instituto de Biotecnologia, Universidade de Caxias do Sul/UCS, Rua Francisco Getúlio Vargas, 1130, 95070-560 Caxias do Sul, RS, Brasil
| |
Collapse
|
5
|
Wang XX, Zhou Q, Pan DB, Deng HW, Zhou AG, Guo HJ, Huang FR. Comparison of Postoperative Events between Spinal Anesthesia and General Anesthesia in Laparoscopic Cholecystectomy: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. BIOMED RESEARCH INTERNATIONAL 2016; 2016:9480539. [PMID: 27525282 PMCID: PMC4976158 DOI: 10.1155/2016/9480539] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Revised: 05/30/2016] [Accepted: 06/13/2016] [Indexed: 02/07/2023]
Abstract
Background. Laparoscopic cholecystectomy is usually carried out under general anesthesia. There were a few studies which have found spinal anesthesia as a safe alternative. We aimed to evaluate the postoperative events between spinal anesthesia and general anesthesia in patients undergoing laparoscopic cholecystectomy. Methods. We searched PubMed, Embase, and Cochrane Library (from inception to January 2016) for eligible studies. The primary outcome was the visual analogue scale score. Secondary outcomes included postoperative nausea and vomiting and urine retention 24 hours postoperatively. We calculated pooled risk ratios and 95% confidence interval using random- or fixed-effects models. Results. Eight trials involving 723 patients were listed. Meta-analysis showed that patients in spinal anesthesia groups have lower visual analogue scale score 24 hours postoperatively. There were significant decreases in the occurrence of postoperative nausea and vomiting in spinal anesthesia group when compared with general anesthesia group (odds ratios: 0.38, 95% confidence interval: 0.19-0.76; P = 0.006) with heterogeneity accepted (I (2) = 13%; P = 0.33), while urine retention rate was increased in patients with spinal anesthesia (odds ratios: 4.95, 95% confidence interval: 1.24-19.71; P = 0.02) without any heterogeneity (I (2) = 0%; P = 0.98). Conclusions. Spinal anesthesia may be associated with less postoperative pain and postoperative nausea and vomiting compared with general anesthesia.
Collapse
Affiliation(s)
- Xian-Xue Wang
- Department of Anesthesiology, The First People's Hospital of Changde City, Changde, Hunan 415003, China
| | - Quan Zhou
- Science & Education Division, The First People's Hospital of Changde City, Changde, Hunan 415003, China
| | - Dao-Bo Pan
- Department of Anesthesiology, The First People's Hospital of Changde City, Changde, Hunan 415003, China
| | - Hui-Wei Deng
- Department of Anesthesiology, The First People's Hospital of Changde City, Changde, Hunan 415003, China
| | - Ai-Guo Zhou
- Department of Anesthesiology, The First People's Hospital of Changde City, Changde, Hunan 415003, China
| | - Hua-Jing Guo
- Department of Anesthesiology, The First People's Hospital of Changde City, Changde, Hunan 415003, China
| | - Fu-Rong Huang
- Department of Anesthesiology, The First People's Hospital of Changde City, Changde, Hunan 415003, China
| |
Collapse
|
6
|
Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG. NAT2 polymorphisms and risk for Parkinson's disease: a systematic review and meta-analysis. Expert Opin Drug Metab Toxicol 2016; 12:937-46. [PMID: 27216438 DOI: 10.1080/17425255.2016.1192127] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Several studies suggested a possible association between certain polymorphisms in the N-acetyl-transferase 2 (NAT2) gene (which encodes a very important enzyme involved in xenobiotic metabolism) and the risk for Parkinson's disease (PD). As the results of studies on this issue are controversial, we conducted a systematic review and a meta-analysis of eligible studies on this putative association. AREAS COVERED The authors revised the relationship between NAT2 polymorphisms and the risk of developing PD using several databases, and performed a meta-analysis using the software Meta-Disc1.1.1. In addition heterogeneity between studies was analyzed. A description of studies regarding gene-gene interactions and gene-environmental interactions involving NAT2 polymorphisms is also made. EXPERT OPINION Despite several recent meta-analyses showing an association between several polymorphisms in genes related with detoxification mechanisms such as cytochrome P4502D6 (CYP2D6), and glutathione transferases M1 and T1 (GSTM1, and GSTT1), data on NAT2 gene polymorphisms obtained from the current meta-analysis do not support a major association with PD risk, except in Asian populations. However, data from many studies are incomplete and therefore insufficient data exists to draw definitive conclusions. Several studies suggesting gene-gene and gene-environmental factors involving NAT2 gene in PD risk await confirmation.
Collapse
Affiliation(s)
- Félix Javier Jiménez-Jiménez
- a Section of Neurology , Hospital Universitario del Sureste , Arganda del Rey , Madrid , Spain.,b Department of Medicine-Neurology, Hospital 'Príncipe de Asturias' , Universidad de Alcalá , Alcalá de Henares , Madrid , Spain
| | | | | | - José A G Agúndez
- c Department of Pharmacology , University of Extremadura , Cáceres , Spain
| |
Collapse
|
7
|
Wang D, Zhai JX, Liu DW. Glutathione S-transferase M1 polymorphisms and Parkinson’s disease risk: a meta-analysis. Neurol Res 2016; 38:144-50. [DOI: 10.1080/01616412.2015.1126996] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
8
|
Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG. Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease. Expert Opin Drug Metab Toxicol 2016; 12:433-48. [PMID: 26910127 DOI: 10.1517/17425255.2016.1158250] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
INTRODUCTION The inheritance pattern of Parkinson's disease (PD) is likely multifactorial (owing to the interplay of genetic predisposition and environmental factors). Many pharmacogenetic studies have tried to establish a possible role of candidate genes in PD risk. Several studies have focused on the influence of genes in the response to antiparkinsonian drugs and in the risk of developing side-effects of these drugs. AREAS COVERED This review presents an overview of current knowledge, with particular emphasis on the most recent advances, both in case-control association studies on the role of candidate genes in the risk for PD as well as pharmacogenetic studies on the role of genes in the development of side effects of antiparkinsonian drugs. The most reliable results should be derived from meta-analyses of case-control association studies on candidate genes involving large series of PD patients and controls, and from genome-wide association studies (GWAS). EXPERT OPINION Prospective studies of large samples involving several genes with a detailed history of exposure to environmental factors in the same cohort of subjects, should be useful to clarify the role of genes in the risk for PD. The results of studies on the role of genes in the development of side-effects of antiparkinsonian drugs should, at this stage, only be considered preliminary.
Collapse
Affiliation(s)
| | | | | | - José A G Agúndez
- b Department of Pharmacology , University of Extremadura , Cáceres , Spain
| |
Collapse
|
9
|
Jia Z, Chen C, Wu Y, Ding F, Tian X, Li W, Wang D, He Q, Ruan D. No difference in clinical outcomes after total knee arthroplasty between patellar eversion and non-eversion. Knee Surg Sports Traumatol Arthrosc 2016; 24:141-7. [PMID: 25274093 DOI: 10.1007/s00167-014-3351-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Accepted: 09/22/2014] [Indexed: 01/14/2023]
Abstract
PURPOSE Multiple surgical techniques in minimally invasive total knee arthroplasty (TKA) are associated with clinical differences. However, whether patellar eversion impairs clinical outcomes remains controversial. We conducted a systematic review of randomized controlled trials (RCTs) to provide current understanding on this topic. METHODS A literature search of the PubMed, Embase, and Cochrane library databases was performed to identify RCTs comparing patellar eversion with patellar non-eversion (PN). Two authors independently selected the studies, assessed methodological quality, and extracted data. RESULTS Five RCTs involving 379 knees were included. The results revealed no significant differences in functional scores, pain, quality of life, quadriceps strength, patellar height, alignment, or complication rate between patellar eversion and PN. Power analysis showed that the power of the individual study and meta-analysis ranged from 5.0 to 70.8%, with the exception of the power of alignment and patellar height in two of the individual studies, which was 100.0 and 99.9%, respectively. CONCLUSIONS Based on the current evidence, patellar eversion during TKA could not definitely lead to inferior postoperative outcomes. Patellar eversion and patellar non-eversion could achieve similar clinical outcomes. LEVEL OF EVIDENCE Systematic review and meta-analysis, Level I.
Collapse
Affiliation(s)
- Zhiwei Jia
- Department of Orthopaedics, Navy General Hospital, No. 6, Fucheng Road, Beijing, 100048, China
| | - Chun Chen
- Department of Orthopaedics, Navy General Hospital, No. 6, Fucheng Road, Beijing, 100048, China.,The Third Clinical Medical College, Southern Medical University, Guangzhou, China
| | - Yaohong Wu
- Department of Orthopaedics, Navy General Hospital, No. 6, Fucheng Road, Beijing, 100048, China.,The Third Clinical Medical College, Southern Medical University, Guangzhou, China
| | - Fan Ding
- Department of Orthopaedics, Wuhan Pu'Ai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xu Tian
- Graduate College, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Wei Li
- Department of Orthopaedics, Navy General Hospital, No. 6, Fucheng Road, Beijing, 100048, China
| | - Deli Wang
- Department of Orthopaedics, Navy General Hospital, No. 6, Fucheng Road, Beijing, 100048, China
| | - Qing He
- Department of Orthopaedics, Navy General Hospital, No. 6, Fucheng Road, Beijing, 100048, China
| | - Dike Ruan
- Department of Orthopaedics, Navy General Hospital, No. 6, Fucheng Road, Beijing, 100048, China.
| |
Collapse
|
10
|
Comparative analysis of four disease prediction models of Parkinson’s disease. Mol Cell Biochem 2015; 411:127-34. [DOI: 10.1007/s11010-015-2574-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 09/26/2015] [Indexed: 12/11/2022]
|
11
|
Wang XX, Zhou Q, Pan DB, Deng HW, Zhou AG, Huang FR, Guo HJ. Dexamethasone versus ondansetron in the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic surgery: a meta-analysis of randomized controlled trials. BMC Anesthesiol 2015; 15:118. [PMID: 26276641 PMCID: PMC4536735 DOI: 10.1186/s12871-015-0100-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Accepted: 08/10/2015] [Indexed: 11/10/2022] Open
Abstract
Background Dexamethasone is an antiemetic alternative to ondansetron. We aimed to compare the effects of dexamethasone and ondansetron in preventing postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic surgery. Methods We searched PubMed, Embase, Medline and Cochrane Library (from inception to July 2014) for eligible studies. The primary outcome was the incidence of PONV during the first 24 h after surgery. The secondary outcomes included PONV in the early postoperative stage (0–6 h), PONV in the late postoperative stage (6–24 h), and the postoperative anti-emetics used at both stages. We calculated pooled risk ratios (RR) and 95 % CIs using random- and fixed-effects models. Results Seven trials involving 608 patients were included in this meta-analysis, which found that dexamethasone had a comparable effectiveness in preventing PONV (RR, 0.91; 95 % CI, 0.73-1.13; P = 0.39) with that of ondansetron within 24 h of laparoscopic surgery, with no evidence of heterogeneity among the studies (I2 = 0 %; P = 0.71). In the early postoperative stage (0–6 h), ondansetron was better at decreasing PONV than dexamethasone (RR, 1.71; 95 % CI, 1.05-2.77; P = 0.03), while in the late postoperative stage (6–24 h), dexamethasone was more effective in preventing PONV than ondansetron (RR, 0.51; 95 % CI, 0.27-0.93; P = 0.03). There was no significant difference in the postoperative anti-emetics used (RR, 0.90; 95 % CI, 0.67-1.19; P = 0.45). Conclusions Dexamethasone was as effective and as safe as ondansetron in preventing PONV. Dexamethasone should be encouraged as an alternative to ondansetron for preventing PONV in patients undergoing laparoscopic surgery.
Collapse
Affiliation(s)
- Xian-Xue Wang
- Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical College, Xuzhou, Jiangsu, China. .,Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, Xuzhou, Jiangsu, China.
| | - Quan Zhou
- Science & Education Division of the First People's Hospital of Changde City, Changde, Hunan, China.
| | - Dao-Bo Pan
- Department of Anesthesiology of the First People's Hospital of Changde City, Changde, Hunan, China.
| | - Hui-Wei Deng
- Department of Anesthesiology of the First People's Hospital of Changde City, Changde, Hunan, China.
| | - Ai-Guo Zhou
- Department of Anesthesiology of the First People's Hospital of Changde City, Changde, Hunan, China.
| | - Fu-Rong Huang
- Department of Anesthesiology of the First People's Hospital of Changde City, Changde, Hunan, China.
| | - Hua-Jing Guo
- Department of Anesthesiology of the First People's Hospital of Changde City, Changde, Hunan, China.
| |
Collapse
|